You are here: RCJournal.com » Clinical Practice Guidelines

Reprinted from the August 1994 issue of RESPIRATORY CARE [Respir Care 1994:39(8):824–829]

AARC Clinical Practice Guideline

Surfactant Replacement Therapy

SRT 1.0 PROCEDURE:

Surfactant replacement therapy in the neonate

SRT 2.0 DESCRIPTION/DEFINITION:

Natural, endogenous surfactant is a compound composed of phospholipids, neutral lipids, and proteins(1-5) that forms a layer between the alveolar surface and the alveolar gas and reduces alveolar collapse by decreasing surface tension within the alveoli.(3-5) Surfactant deficiency is almost always associated with the formation of hyaline membranes in the immature lung and the onset of respiratory distress syndrome (RDS)-a major cause of morbidity and mortality in premature infants.(3) Without surfactant, alveoli may never inflate or may collapse on expiration and require inordinate force to re-expand on inspiration, leading to the development of RDS.(3,5) The incidence of RDS is related more to lung immaturity than to gestational age.(6) However, in general, the more premature the infant, the less the surfactant production and the higher the probability for RDS.(4,6) Direct tracheal instillation of surfactant has been shown to reduce mortality and morbidity in infants with RDS.(7-25)

Surfactant can be extracted from animal lung lavage and from human amniotic fluid or produced from synthetic materials.

Two basic strategies for surfactant replacement have emerged: (1) prophylactic or preventive treatment in which surfactant is administered at the time of birth or shortly thereafter to infants who are at high risk for developing RDS and (2) rescue or therapeutic treatment in which surfactant is administered after the initiation of mechanical ventilation in infants with clinically confirmed RDS.(2,10-12,26,27)

SRT 3.0 SETTINGS:

Administered by trained personnel in
3.1 Delivery room
3.2 Neonatal intensive care unit

SRT 4.0 INDICATIONS:

4.1 Prophylactic administration may be indicated in
4.1.1 infants at high risk of developing RDS because of short gestation (< 32 weeks)(8,10-12,21,25-29) or low birthweight (< 1,300 g),(21-25,28) which strongly suggest lung immaturity.
4.1.2 infants in whom there is laboratory evidence of surfactant deficiency such as lecithin/sphingomyelin ratio less than 2:1,11,14,28,30,31 bubble stability test indicating lung immaturity,(15,32) or the absence of phosphatidylglycerol.(11,14,22-24,28,30)
4.2 Rescue or therapeutic administration is indicated in preterm or full-term infants
4.2.1 who require endotracheal intubation and mechanical ventilation because of
4.2.1.1 increased work of breathing as indicated by an increase in respiratory rate, substernal and suprasternal retractions, grunting, and nasal flaring.(8,11,14-16,29,33-35)
4.2.1.2 increasing oxygen requirements as indicated by pale or cyanotic skin color, agitation, and decreases in PaO2, SaO2, or SpO2 mandating an increase in FIO2 above 0.(4011,12,15,26,33,36-38)
and
4.2.2 have clinical evidence of RDS,(13,39) including
4.2.2.1 chest radiograph characteristic of RDS,(8,11-16,33,34,36,37,40-42)
4.2.2.2 mean airway pressure greater than 7 cm H2O to maintain an adequate PaO2, SaO2, or SpO2.(11,14,15,26,43)

SRT 5.0 CONTRAINDICATIONS:

Relative contraindications to surfactant administration are
5.1 the presence of congenital anomalies incompatible with life beyond the neonatal period,(8,14,15,26,28,29,31,33,36,41,44)
5.2 respiratory distress in infants with laboratory evidence of lung maturity.(9,14,27-29,33,36,41)

SRT 6.0 HAZARDS/COMPLICATIONS:

6.1 Procedural complications resulting from the administration of surfactant include
6.1.1 plugging of endotracheal tube (ETT) by surfactant;(2)
6.1.2 hemoglobin desaturation and increased need for supplemental O2;(11,33,41)
6.1.3 bradycardia due to hypoxia;(9,33,41,45)
6.1.4 tachycardia due to agitation, with reflux of surfactant into the ETT;(34,41)
6.1.5 pharyngeal deposition of surfactant;
6.1.6 administration of surfactant to only one lung;
6.1.7 administration of suboptimal dose secondary to miscalculation or error in reconstitution.
6.2 Physiologic complications of surfactant replacement therapy include
6.2.1 apnea,(7,13,15)
6.2.2 pulmonary hemorrhage,(12,15,18,32,34,38,46,47)
6.2.3 mucus plugs,(48)
6.2.4 increased necessity for treatment for PDA,(18,29,30)
6.2.5 marginal increase in retinopathy of prematurity,(11)
6.2.6 barotrauma resulting from increase in lung compliance following surfactant replacement and failure to change ventilator settings accordingly.(30,49)

SRT 7.0 LIMITATION OF METHOD:

7.1 Surfactant administered prophylactically may be given to some infants in whom RDS would not have developed.(10,12,26,33)
7.2 When surfactant is administered prophylactically in the delivery room, ETT placement may not have been verified by chest radiograph resulting in the inadvertent administration to only one lung or to the stomach.(26)
7.3 Prophylactic surfactant administration may delay patient stabilization.(26)
7.4 Atelectasis and lung injury may occur prior to therapeutic administration.(26,33)
7.5 Tracheal suctioning should be avoided following surfactant administration.(9,11,13,14,27,33,38,44,50)
7.6 Not all infants who are treated with a single dose of surfactant experience a positive response39 or the response may be transient.
7.7 Positioning recommended for surfactant administration may further compromise the unstable infant.(9,11,12,14,16,28,33,38-40)

SRT 8.0 ASSESSMENT OF NEED:

Determine that valid indications are present.
8.1 Assess lung immaturity prior to prophylactic administration of surfactant by gestational age and birthweight and/or by laboratory evaluation of tracheal or gastric aspirate.
8.2 Establish the diagnosis of RDS by chest radiographic criteria and the requirement for mechanical ventilation in the presence of short gestation and/or low birthweight.

SRT 9.0 ASSESSMENT OF OUTCOME:

9.1 Reduction in FIO2 requirement(12,33,34,36-39,41,44)
9.2 Reduction in work of breathing(51)
9.3 Improvement in lung volumes and lung fields as indicated by chest radiograph(13,16,33,40)
9.4 Improvement in pulmonary mechanics (eg, compliance, airways resistance, VT, VE, transpulmonary pressure) and lung volume (ie, FRC)(42,43,50,52-59)
9.5 Reduction in ventilator requirements (PIP, PEEP, Paw)(2,8,9,12,13,27,30,33,36-39,41,44,50,52)
9.6 Improvement in ratio of arterial to alveolar PO2 (a/A PO2), oxygen index(13,16,28,30,33,34,37-41,44)

SRT 10.0 RESOURCES:

Administration procedures recommended for specific preparations of surfactant should be adhered to.
10.1 Equipment(10-14,16,26-28,33,34,39,40,50,60)
10.1.1 Administration equipment
10.1.1.1 Syringe containing the ordered dose of surfactant, warmed to room temperature(11,12,16,38,40)
10.1.1.2 5-Fr feeding tube or catheter, or endotracheal tube connector with delivery port
10.1.1.3 Mechanical ventilator or manual ventilator (resuscitation bag)(8,16,33,36,38-40,44,50,52)
10.1.2 Resuscitation equipment
10.1.2.1 Laryngoscope and endotracheal tube(10-12,14,16,26,38)
10.1.2.2 Manual resuscitation bag(9-12,16,26-28,36,39,40,50) and airway manometer
10.1.2.3 Blended oxygen source(9,16,28,44)
10.1.2.4 Suction equipment (ie, catheters, sterile gloves, collecting bottle and tubing, and vacuum generator)(9,33,50,60)
10.1.2.5 Radiant warmer ready for use
10.1.3 Monitoring equipment
10.1.3.1 Neonatal tidal volume monitor if available(50)
10.1.3.2 Airway pressure monitor
10.1.3.3 Pulse oximeter or transcutaneous PCO2 monitor(11,26,34,39-41,52)
10.1.3.4 Cardiorespiratory monitor
10.2 Personnel-- Surfactant replacement therapy should be performed under the direction of a physician by credentialed personnel (eg, CRTT, RRT, RN) who competently demonstrate
10.2.1 proper use, understanding, and mastery of the equipment and technical aspects of surfactant replacement therapy;
10.2.2 comprehensive knowledge and understanding of neonatal ventilator management and pulmonary anatomy and pathophysiology;
10.2.3 neonatal patient assessment skills, including the ability to recognize and respond to adverse reactions and/or complications of the procedure;
10.2.4 knowledge and understanding of the patient's history and clinical condition;
10.2.5 knowledge and understanding of airway management;
10.2.6 ability to interpret monitored and measured blood gas variables and vital signs;
10.2.7 proper use, understanding, and mastery of emergency resuscitation equipment and procedures;
10.2.8 ability to evaluate and document outcome (Section 9.0);
10.2.9 understanding and proper application of Universal Precautions.

SRT 11.0 MONITORING:

The following should be monitored as part of surfactant replacement therapy.
11.1 Variables to be monitored during surfactant administration
11.1.1 Proper placement and position of delivery device
11.1.2 FIO2 and ventilator settings(8,9,11,13-15,27-29,33,36,38,44)
11.1.3 Reflux of surfactant into ETT(34,41)
11.1.4 position of patient (ie, head direction)(9,11,33)
11.1.5 Chest-wall movement(61)
11.1.6 Oxygen saturation by pulse oximetry(11,26,34,39-41,52)
11.1.7 Heart rate, respirations, chest expansion, skin color, and vigor(16,26,27,34,41,45,52)
11.2 Variables to be monitored after surfactant administration
11.2.1 Invasive and noninvasive measurements of arterial blood gases(8,9,11,12-16,26-29,33,36,38,39,41,44)
11.2.2 Chest radiograph(11-16,28,36,38-40,44)
11.2.3 Ventilator settings (PIP, PEEP, Paw) and FIO2(8,9,11,13-16,28,29,33,36,38)
11.2.4 Pulmonary mechanics and volumes
11.2.5 Heart rate, respirations, chest expansion, skin color, and vigor(16,26,27,34,41,45,52)
11.2.6 Breath sounds(11,38)
11.2.7 Blood pressure1(3,16,33,40,44,45)

SRT 12.0 FREQUENCY:

Repeat doses of surfactant are contingent upon the continued diagnosis of RDS. The frequency with which surfactant replacement is performed should depend upon the clinical status of the patient and the indication for performing the procedure. Additional doses of surfactant, given at 6- to 24-hour intervals, may be indicated in infants who experience increasing ventilator requirements or whose conditions fail to improve after the initial dose.(7,9,11,12,14,15,26,30,34,37,39,52)

SRT 13.0 INFECTION CONTROL:

13.1 Universal Precautions(62) should be implemented.
13.2 Aseptic technique should be practiced.
13.3 Appropriate infection control guidelines for the patient should be posted and followed.
Perinatal-Pediatrics Guidelines Committee:

Lynne K Bower RRT, Chairman, Boston MA
Sherry L Barnhart RRT, Mattoon IL
Peter Betiti BS RRT, Boston MA
Barbara Hendon BA RRT RCP, Wylie TX
Joanne Masi-Lynch BS RRT, Salt Lake City UT
Barbara G Wilson MEd RRT, Durham NC

REFERENCES
  1. Jobe A. Surfactant treatment for respiratory distress syndrome. Respir Care 1986;31(6):467-476.
  2. Berry D. Neonatology in the 1990's: surfactant replacement therapy becomes a reality. Clin Pediatr 1991;30(3):167-170.
  3. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:517-523.
  4. von Neergard K. Neue Auffassungen über einen Grundbegriff der Atemmechanik: die Retraktionskraft der Lunge, äbhangig von der Oberflächenspannung in den Alveolen. Z Ges Exp Med 1929;66:373.
  5. Hallman M, Teramo K, Ylikorkala O, Merritt TA. Natural surfactant substitution in respiratory distress syndrome. J Perinat Med 1987;15:463-468.
  6. Stableman MT. Acute respiratory disorders in the newborn. In: Avery G, ed. Neonatology. Philadelphia: JB Lippincott, 1975:221-249.
  7. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics 1993;92(2):191-196.
  8. Lang MJ, Hall RT, Reddy NS, Kurth CG, TA Merritt. A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. J Pediatr 1990;116(2):295-300.
  9. Hoekstra RE, Jackson JC, Myers TF, Frantz ID III, Stern ME, Powers WF, et al. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics 1991;88(1):10-18.
  10. Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics 1993;92(1):90-98.
  11. Merritt TA, Hallman M, Berry C, Pohjavuori M, Edwards DK, Jaaskelainen J, et al. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr 1991;118(4):581-594.
  12. Dunn MS, Shennan AT, Zayack D, Possmayer F. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics 1991;87(3):377-386.
  13. Long W, Thompson T, Sundell H, Schumacher R, Volberg F, Guthrie R, et al. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. J Pediatr 1991;118(4):595-605.
  14. Liechty EA, Donovan E, Purohit D, Gilhooly J, Feldman B, Noguchi A, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics 1991;88(1):19-28.
  15. Long W, Corbet A, Cotton R, Courtney S, Mc Guiness G, Walter D, et al. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. N Engl J Med 1991;325(24):1696-1703.
  16. Fujiwara T, Konishi M, Chida S, Okuyama K, Ogawa Y, Takecuchi Y, et al. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. Pediatrics 1990;86(5):753-764.
  17. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant--the judgement of OSIRIS. Lancet 1992;340(8832):1363-1369.
  18. Ferrara TB, Hoekstra RE, Couser RJ, Gaziano EP, Calvin SE, Payne NR, et al. Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy. J Pediatr 1994;124(1):119-124.
  19. Hallman M, Merritt TA, Jarvenpaa A-L, Boynton B, Mannino F, Gluck L, et al. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr 1985;106(6):963-969.
  20. Berry DD, Pramanik AK, Phillips JB III, Buchter DS, Kanarek KS, Easa D, et al. Comparison of the effect of three doses of a synthetic surfactant on the alveolar-arterial oxygen gradient in infants weighing > or = 1250 grams with respiratory distress syndrome. J Pediatr 1994;124(2):294-301.
  21. Gortner L, Bartmann P, Pohlandt F, Bernsau U, Porz F, Hellwege HH, et al. Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: a multicenter controlled clinical trial. Pediatr Pulmonol 1992;14(1):4-9.
  22. Corbet AJ, Long WA, Murphy DJ, Garcia-Prats JA, Lombardy LR, Wold DE. Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant. J Paediatr Child Health 1991;27(4):245-249.
  23. Bose C, Corbet A, Bose G, Garcia-Prats J, Lombardy L, Wold D, et al. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr 1990;117:947-953.
  24. Corbet A, Bucciarelli R, Goldman S, Mammel M, Wold D, Long W, and the American Exosurf Pediatric Study Group. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr 1991;118(2):277-284.
  25. Merritt TA, Hallman M, Bloom BT, Berry C, Benirschke K, Sahn D, et al. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 1986;315(13):785-790.
  26. Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med 1991;324(13):865-871.
  27. Egberts J, de Winter JP, Sedin G, deKleine MJ, Broberger U, van Bel F, et al. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial. Pediatrics 1993;92(6):768-774.
  28. Soll RF, Hoekstra RE, Fangman JJ, Corbet AJ, Adams JM, James LS, et al. Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Pediatrics 1990;85(6):1092-1102.
  29. Heldt GP, Pesonen E, Merritt TA, Elias W, Sahn DJ. Closure of the ductus arteriosus and mechanics of breathing in preterm infants after surfactant replacement therapy. Pediatr Res 1989;25(3):305-310.
  30. Hallman M, Merritt TA, Bry K, Berry C. Association between neonatal care practices and efficacy of exogenous human surfactant: results of a bicenter randomized trial. Pediatrics 1992;91(3):552-560.
  31. Lotze A, Knight GR, Martin GR, Bulas DI, Hull WM, O'Donnell RM, et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 1993;122(2):261-268.
  32. Raju TN, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a meta-analysis. J Pediatr 1993;123(4):603-610.
  33. Horbar JD, Soll RF, Sutherland JM, Kotagal U, Philip AGS, Kessler DL, et al. A multicenter randomized, placebo-controlled trial of surfactant therapy for respiratory distress syndrome. N Engl J Med 1989;320(15): 959-965.
  34. Horbar JD, Wright LL, Soll RF, Fanaroff AA, Korones SB, Shankaran S, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993;123(5): 757-766.
  35. Hazan J, Chessex P, Piedboeuf B, Bourgeois M, Bard H, Long W. Energy expenditure during synthetic surfactant replacement therapy for neonatal respiratory distress syndrome. J Pediatr 1992;120(2, Part 2):S29-S33.
  36. Speer CP, Harms K, Herting E, Neumann N, Curstedt T, Robertson B. Early versus late surfactant replacement therapy in severe respiratory distress syndrome. Lung 1990;168(Suppl):870-876.
  37. Khammash H, Perlman M, Wojtulewicz, J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993;92(1):135-139.
  38. Stevenson D, Walther F, Long W, Sell M, Paul T, Gong A, et al. Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. J Pediatr 1992;120(2, Part 2):S3-S12.
  39. Dunn MS, Shennan AT, Possmayer F. Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome. Pediatrics 1990;86(4):564-571.
  40. Hellstrom-Westas L, Bell AH, Skov L, Greisen G, Svenningsen NW. Cerebroelectrical depression following surfactant treatment in preterm neonates. Pediatrics 1992;89(4):643-647.
  41. Zola EM, Gunkel JH, Chan RK, Lim MO, Knox I, Feldman BH, et al. Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr 1992;122(3):453-459.
  42. Annibale DJ, Hulsey TC, Wallin LA, Engstrom PC. Clinical diagnosis and management of respiratory distress in preterm neonates: effect of participation in a controlled trial. Pediatrics 1992;90(3):397-400.
  43. Goldman SL, Bosque E, McCann E, Lewis K. Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant. J Pediatr 1992;120(2, Part 2):S25-S28.
  44. Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller O, et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 1992; 89(1):13-20.
  45. Gunkel JH, Banks PL. Surfactant therapy and intracranial hemorrhage: review of the literature and results of new analyses. Pediatrics 1993;92(6):775-786.
  46. Zola EM, Overbach AM, Gunkel JH, Mitchell BR, Nagle BT, DeMarco NG, et al. Treatment investigational new drug experience with Survanta (beractant). Pediatrics 1993;91(3):546-551.
  47. van Houten J, Long W, Mullett M, Finer N, Derleth D, McMurray B, et al. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: an autopsy evaluation. J Pediatr 1992;120(2, Part 2):S40-S44. Erratum appears in J Pediatr 1992;120(5):762.
  48. Rubin BK, Ramirez O, King M. Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy. Chest 1992;101(4):1080-1085.
  49. Goldsmith LS, Greenspan JS, Rubenstein SD, Wolfson MR, Shaffer TH. Immediate improvement in lung volume after exogenous surfactant: alveolar recruitment versus increased distention. J Pediatr 1991;119(3):424-428.
  50. Bhutani VK, Abbasi S, Long WA, Gerdes JS. Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant. J Pediatr 1992;120(2, Part 2):S18-S24.
  51. Bhat R, Dziedzic K, Bhutani VK, Vidyasagar D. Effect of single dose surfactant on pulmonary function. Crit Care Med 1990;18(6):590-595.
  52. Abbasi S, Bhutani VK, Gerdes JS. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. J Pediatr 1993;122:446-452.
  53. Davis JM, Veness-Meehan K, Notter RH, Bhutani VK, Kendig JW, Shapiro DL. Changes in pulmonary mechanics after the administration of surfactant to infants with respiratory distress syndrome. N Engl J Med 1988;319(8):476-479.
  54. Armsby DH, Bellon G, Carlisle K, Rector D, Baldwin R, Stevenson DK, et al. Delayed compliance increase in infants with respiratory distress syndrome following synthetic surfactant. Pediatr Pulmonol 1992;14(4):206-213.
  55. Couser RJ, Ferrara TB, Ebert J, Hoekstra RE, Fangman JJ. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr 1990;116(1):119-124.
  56. Svenningsen NW, Bjorklund L, Vilstrup C, Werner O. Lung mechanics (FRC and static pressure-volume diagram) after endotracheal surfactant instillation: preliminary observations. Biol Neonate 1992;61(Suppl 1):44-47.
  57. Pfenninger J, Aebi C, Bachmann D, Wagner BP. Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (Exosurf). Pediatr Pulmonol 1992;14(1):10-15.
  58. Kelly E, Bryan H, Possmayer F, Frndova H, Bryan C. Compliance of the respiratory system in newborn infants pre- and postsurfactant replacement therapy. Pediatr Pulmonol 1993;15(4):225-230.
  59. Yuksel B, Greenough A, Gamsu HR. Respiratory function at follow-up after neonatal surfactant replacement therapy. Respir Med 1993;87(3):217-221.
  60. Kääpä P, Seppanen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr 1993;123(1):115-119.
  61. Sitler CG, Turnage CS, McFadden BE, Smith EO, Adams JM. Pump administration of exogenous surfactant: effects on oxygenation, heart rate, and chest wall movement of premature infants. J Perinatol 1993;13(3):197-200.
  62. Centers for Disease Control. Update: Universal Precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 1988;37:377-382,387-388.

Interested persons may copy these Guidelines for noncommercial purposes of scientific or educational advancement. Please credit AARC and Respiratory Care Journal.

Reprinted from the August 1994 issue of RESPIRATORY CARE [Respir Care 1994:39(8):824–829]

You are here: RCJournal.com » Clinical Practice Guidelines